<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01065441</url>
  </required_header>
  <id_info>
    <org_study_id>ITL-002-HMC</org_study_id>
    <nct_id>NCT01065441</nct_id>
  </id_info>
  <brief_title>Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer</brief_title>
  <official_title>A Phase I/II Study of an Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Har-Noy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunovative Therapies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of&#xD;
      antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of&#xD;
      a selected tumor by cryoablation (killing using extreme cold) and the adjuvant is&#xD;
      intentionally mis-matched immune cells (AlloStim-TM) engineered to produce inflammatory&#xD;
      cytokines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II clinical study to investigate the optimal protocol and indication for&#xD;
      creating a personalized anti-tumor vaccine within the body of patients with cancer. The aim&#xD;
      of the study is to evaluate the safety of administration and anti-tumor effect of a vaccine&#xD;
      protocol that has three separate steps. Cancer patients generally present with an immune&#xD;
      response to cancer biased to a Th2 response, while a Th1 response is considered necessary for&#xD;
      mediating anti-tumor immunity. The first step of the study consists of multiple intradermal&#xD;
      priming doses of AlloStimTM. The aim of this step is to create Th1 immunity to the&#xD;
      alloantigens in AlloStimTM, thus increasing the number of Th1 cells in circulation. The&#xD;
      second step of the protocol involves the cryoablation of a selected tumor lesion followed by&#xD;
      an intratumoral AlloStimTM injection. The aim of this step is to generate tumor-specific CTL&#xD;
      killer cells in the circulation. The final step is an intravenous infusion of AlloStimTM. The&#xD;
      aim of this step is to activate circulating Th1 cells, killer cells, and natural killer&#xD;
      cells. The further aim of this step is to create an inflammatory environment that can&#xD;
      break-down the ability of the tumor to avoid an anti-tumor immune response. In patients with&#xD;
      partial responses and recurrence of disease, additional intravenous &quot;booster&quot; infusions are&#xD;
      utilized to reactivate the circulating immune cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the evaluation of any drug-related toxicity associated with AlloStimTM administration as well as the reversibility of such toxicity.</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary end-point is the evaluation of the anti-tumor effect of AlloStimTM administration.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The tertiary end-point is the evaluation of the immunological response to AlloStim-TM administration.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Solid Tumors Stage II, Stage III and Stage IV</condition>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10^7 cells</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Percutaneous cryoablation of selected tumor lesion under CT or US guidance</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10^7 cells</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>intravenous AlloStim-TM at doses between 1 x 10^7 to 1 x 10^9 cells</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10^7 cells.</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Stage II-IV including breast cancer, colorectal cancer, non-small cell lung cancer,&#xD;
             ovarian or other gynecological cancer, prostate cancer, pancreatic or other GI cancer,&#xD;
             melanoma, head or neck cancer or lymphoma/plasmacytoma.&#xD;
&#xD;
          -  Measurable disease determined upon review of abdominal and/or chest CT scan within 60&#xD;
             days of evaluation for study inclusion with a target tumor lesion for cryoablation or&#xD;
             alcohol ablation located in liver, kidney, bone, lung, adrenal, pancreas, lymph node,&#xD;
             skin, neck or prostate deemed to be accessible for percutaneous access or&#xD;
             carcinomatosis or malignant ascites or malignant pleural effusion.&#xD;
&#xD;
          -  When applicable, acceptable cryoablation procedure technique risk: the target tumor&#xD;
             for ablation must have adequate distance from adjacent vasculature and other organs to&#xD;
             permit safe application of cryoprobe (generally, more than a 2.5cm clearance of the&#xD;
             cryoprobe from any vital structure such as the bowel, inferior vena cava, or aorta).&#xD;
             The safety assessment of the cryoprobe placement will be made an attending radiologist&#xD;
             based on imaging studies.&#xD;
&#xD;
          -  Life expectancy &gt;90 days&#xD;
&#xD;
          -  No bevacizumab (Avastin®) within 6 weeks of planned cryoablation procedure&#xD;
&#xD;
          -  ECOG status 0-2&#xD;
&#xD;
          -  No concurrent medication known to interfere with platelet function or coagulation&#xD;
             (e.g., aspirin, ibuprofen, clopidogrel, or warfarin) unless such medications can be&#xD;
             discontinued for an appropriate time period based on the drug half-life and known&#xD;
             activity (e.g., aspirin for 7 days) prior to cryoablation procedure&#xD;
&#xD;
          -  No low molecular weight heparin preparations unless can be discontinued 8 hours prior&#xD;
             to cryoablation&#xD;
&#xD;
          -  At least 2 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,200/mm3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
          -  PT/INR ≤ 1.5&#xD;
&#xD;
             o INR correctable to ≤ 1.5 or a PT/PTT correctable to normal limits. Patients&#xD;
             receiving anti-coagulation treatment with an agent such as warfarin or heparin may be&#xD;
             allowed to participate. For patients on warfarin, the INR should be monitored weekly&#xD;
             prior to the cryoablation day to assure INR is stable. However, heparin or warfarin&#xD;
             must be withheld prior to cryoablation such that the above criteria are met.&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times normal (≤ 5 times normal if liver involvement)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or (SGOT) ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or (SGPT) ≤ 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or lactating&#xD;
&#xD;
          -  Patients with child bearing potential must agree to use adequate contraception&#xD;
&#xD;
          -  No psychiatric or addictive disorders or other condition that, in the opinion of the&#xD;
             investigator, would preclude study participation&#xD;
&#xD;
          -  Study specific informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking anticoagulant medication for concomitant medical condition (unless can be&#xD;
             safely discontinued for cryoablation procedure)&#xD;
&#xD;
          -  Prior allogeneic bone marrow/stem cell or solid organ transplant&#xD;
&#xD;
          -  Chronic use (&gt; 2 weeks) of greater than physiologic doses of a corticosteroid agent&#xD;
             (dose equivalent to &gt; 10 mg/day of prednisone) within 30 days of the first day of&#xD;
             study drug treatment&#xD;
&#xD;
             o Topical and inhaled corticosteroids are permitted&#xD;
&#xD;
          -  Concomitant active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis,&#xD;
             autoimmune thyroid disease, uveitis)&#xD;
&#xD;
          -  Prior experimental cancer vaccine treatment (e.g., dendritic cell therapy, heat shock&#xD;
             vaccine)&#xD;
&#xD;
          -  Immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or&#xD;
             tacrolimus within 3 months of study entry&#xD;
&#xD;
          -  History of blood transfusion reactions&#xD;
&#xD;
          -  Known allergy to bovine products&#xD;
&#xD;
          -  Know allergy to murine products&#xD;
&#xD;
          -  Progressive viral or bacterial infection&#xD;
&#xD;
             o All infections must be resolved and the patient must remain afebrile for seven days&#xD;
             without antibiotics prior to being placed on study&#xD;
&#xD;
          -  Cardiac disease of symptomatic nature or cardiac ejection fraction &lt; 45%&#xD;
&#xD;
          -  Symptomatic pulmonary disease or FEV1, FVC, and DLCO ≤ 50% predicted&#xD;
&#xD;
          -  History of HIV positivity or AIDS o HBV and/or HCV positivity is permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamar Peretz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Michael Har-Noy</last_name>
    <role>Study Chair</role>
    <affiliation>Immunovative Therapies, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah-Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.immunocare.net</url>
    <description>patient information website</description>
  </link>
  <reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.</citation>
    <PMID>18834631</PMID>
  </reference>
  <reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Slavin S. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity. Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007. Epub 2008 Jun 18.</citation>
    <PMID>18565579</PMID>
  </reference>
  <reference>
    <citation>Har-Noy M, Slavin S. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Med Hypotheses. 2008;70(6):1186-92. Epub 2007 Dec 3.</citation>
    <PMID>18054441</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 7, 2010</study_first_submitted>
  <study_first_submitted_qc>February 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2010</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Immunovative Therapies, Ltd.</investigator_affiliation>
    <investigator_full_name>Michael Har-Noy</investigator_full_name>
    <investigator_title>Investigator: Dept of Bone Marrow Transplantation and Immunotherapy</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>melanoma</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>GI cancer</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

